Travoprost intraocular implant - Glaukos

Drug Profile

Travoprost intraocular implant - Glaukos

Latest Information Update: 03 Apr 2017

Price : $50

At a glance

  • Originator Dose medical corporation
  • Developer Glaukos Corporation
  • Class Antiglaucomas; Prostaglandins; Small molecules
  • Mechanism of Action Prostaglandin F2 alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Glaucoma

Most Recent Events

  • 01 Mar 2016 Phase-II clinical trials in Glaucoma in USA (Implant) (NCT02754596)
  • 07 Jan 2016 Glaukos plans a phase II trial for Glaucoma in the US
  • 23 Jun 2015 Phase-I clinical trials in Glaucoma in Armenia (Implant) (Glaukos Form S-1/A, June 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top